Introduction
============

Recent advances in cancer diagnostic and therapeutic tools have increased the success rate and survival of cancer patients. However, treatment of metastatic cancers continues to be a challenge. Cancer metastasis involves dissemination of cancer cells from their primary site and establishment at either the surrounding or distant tissues by invasion through the extracellular matrix (ECM) or the blood/lymph streams, respectively. It is a complex multi-step phenomenon and involves interplay of several factors that enable cancer cells to acquire invasiveness and intravasate into circulatory system, survive in the blood or lymph circulation, form microvasculature and extravasate to form tumor mass at distant organs [@B1]-[@B3]. These involve activation of several processes at cellular level including epithelial-mesenchymal transition (EMT), motility, adhesion and invasiveness that are regulated by activation of oncogenes, proteases and other tumor-microenvironment components and inactivation of tumor suppressor proteins and apoptosis-mediating factors [@B4]-[@B7]. Chemotherapeutic drugs target these pro-cancer signaling pathways. However, most of the available drugs also target the noncancerous normal dividing cells in the body resulting in undesired adverse side-effects including low-immune response, hair loss, fatigue, nausea and hormone-imbalance. Furthermore, most of the anticancer drugs show low efficacy for metastatic cancer cells resulting in either treatment failure or relapse. Chemoresistance and radioresistance of cancer cells and nonspecific toxicity of chemical drugs towards normal cells are the major hurdles the cancer treatment. Several epidemiological studies have suggested that the consumption of fruits and vegetables lower cancer risk. Several plant-derived polyphenols including curcumin, genistein, silymarin, caffeic acid phenethyl ester, resveratrol, green tea polyphenols, flavopiridol, emodin and piperine have hence been investigated for their chemo-therapeutic and -preventive properties and for sensitization of tumor cells to chemo- and radio-therapeutic agents [@B8]-[@B14]. Owing to their safety, availability and economic aspects, natural chemicals are gaining increasing focus in research aiming to understand their cancer-preventive and -curative activities, and their mechanism(s) of action.

Propolis is a natural amalgam produced by honeybees by mixing plant materials with wax and resin to build their hives. In folk medicine, it has been used for anti-bacterial, anti-inflammatory, wound healing, skin infections, gastro-intestinal disorders, immunomodulation and cardiovascular benefits. CAPE (Caffeic Acid Phenethyl Ester) is an active phenolic compound isolated from propolis. It was ascribed several activities, previously detected in propolis, and has been known as an anti-mitogenic and anticancer natural drug [@B15],[@B16]. Several studies have shown that CAPE and its derivative compounds exhibit selective toxicity to transformed/cancer cells [@B17]-[@B23]. CAPE- and Artepillin C (ARC)- rich propolis extracts were suggested as natural anti-PAK1 inhibitors and NF1/NF2 remedies [@B24],[@B25]. CAPE was shown to inhibit TPA (12-O-tetradecanoylphorbol-13-acetate)-induced tumors [@B26],[@B27], and suggested as an anticancer drug for treatment of colorectal carcinoma [@B28], hepatoma [@B29] and gastric carcinoma [@B30]. CAPE-induced cell cycle arrest and apoptosis are mediated by down-regulation of beta-catenin [@B31],[@B32] and p38MAPK [@B33] signaling. It was shown to inhibit NF-kappaB, COX-2 [@B34],[@B35] and stimulate human anti-oxidative response element-mediated expression of the NAD (P) H: quinone oxidoreductase (NQO1) gene [@B36]. CAPE was shown to (i) restore intercellular communication through gap junctions, regulated by phosphorylation of connexin 43 [@B35], (ii) cause rearrangement of actin cytoskeleton and loss of focal adhesion plaques causing reduced cell invasion [@B37]. It inhibited growth of cancer cells in soft agar through downregulation of p21^ras^protein [@B38]. Consistent with the *in vitro* reports, anticancer activity of CAPE was endorsed by *in vivo* studies in mice [@B39]-[@B41]. CAPE and its derivative, caffeic acid phenylpropyl ester (CAPE), were shown to inhibit PI3-K/Akt, AMPK and m-TOR signaling cascades both *in vitro* and *in vivo*[@B41]. Although such reports proposed CAPE as a natural drug for cancer prevention and treatment, molecular studies are warranted to clarify its mechanism of action and rational designing of its derivatives.

Cyclodextrin (CD) is produced from starch by the process of enzymatic conversion. It is widely used in food, agriculture, pharmaceutical, chemical and environmental engineering. It is also used in drug delivery, because of its structure with hydrophobic inside and a hydrophilic outside that enhances the solubility and bioavailability of compounds. γCD, widely accepted for use in food, pharmaceutical, agricultural and chemical industry constitutes of 8 glucose monomers arranged in the form of a cyclic ring. It has been reported to enhance the bioavailability of hydrophobic ingredients such as coenzyme Q10 [@B42]-[@B44].

In the present study, we generated conjugate of CAPE and γCD and investigated their anticancer and anti-metastasis potential using a variety of cancer cells *in vitro*and *in vivo*.

Materials and methods
=====================

Cell culture
------------

Human lung carcinoma (A549), fibrosarcoma (HT1080), melanoma (G361), osteosarcoma (U2OS), breast carcinoma (MCF-7 and MDA-MB-231), were obtained from Japanese Collection of Research Bioresources. Mortalin overexpressing metastatic derivatives were obtained by retrovirus driven overexpression of mortalin as described earlier [@B45]. Cells were cultured in DMEM (Life Technologies, Carlsbad, CA, USA)-supplemented with 10% fetal bovine serum at 37°C, in an atmosphere of 5% CO2 and 95% air in a humidified incubator. CAPE (Caffeic Acid Phenethyl Ester) and CAPE-γCD (Caffeic Acid Phenethyl Ester-Gamma Cyclodextrin complex) were dissolved in dimethylsulfoxide (DMSO) to make 1 mM stocks and added to the complete cell culture medium to obtain the working concentrations as indicated. All the biochemical and imaging assays were performed on sub-confluent (60-70%) cultures.

Preparation of CAPE-γCD complex
-------------------------------

To an aqueous solution of γCD, a solution of CAPE and ethanol in equal molar ratio was added gradually at 25^o^C. The mixture was incubated for 20 h with continuous stirring following which CAPE-γCD as the precipitation was generated. After removing supernatant from the resulting mixture by centrifugation, crude CAPE-γCD was washed with water and chloroform and dried *in vacuo*. CAPE-γCD thus obtained was used in the present study.

Cytotoxicity and growth inhibition assay
----------------------------------------

The effect of CAPE and CAPE-γCD on cell viability was determined using quantitative colorimetric MTT \[3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide\] assay dependent on the mitochondrial activity of living cells (Sigma Aldrich, Japan). Cells (5 X 10^3^)/well were plated in 96-well plates. After overnight incubation, the cells were treated with CAPE and CAPE-γCD as indicated. MTT (0.5 mg/ml) was added to the cell culture medium at the end of treatments and incubated for 4 h in a humidified incubator (37ºC and 5% CO~2~). MTT-containing medium was replaced with DMSO (100 µL) in each well to dissolve purple formazan crystals. Absorbance was measured at 550 nm using spectrophotometer (TECAN, Switzerland). Experiments were done in triplicates. The standard deviation & statistical significance of the data were determined by unpaired t-test using GraphPad software.

Morphological observations
--------------------------

The cells were cultured in 12-well plates and upon reaching 60% confluency they were treated with different concentrations of CAPE, CAPE-γCD and γCD. After 48-72 h, morphological changes were recorded with a phase contrast microscope.

Colony-forming assays
---------------------

500 cells were plated in a six-well plate. After overnight incubation, the cells were treated with media-supplemented with CAPE. The treated cells were then left to form colonies for the next 10-15 days with a regular change in medium on every third day. Colonies were fixed in methanol, stained with 0.1% crystal violet solution, photographed and counted.

Cell cycle analysis
-------------------

MCF-7 and MDA-MB-231 cells were plated in 6 well plates at density of 2 X 10^5^ cells/well. After 24 h of seeding, cells were treated with CAPE for 24-36 h followed by harvesting by trypsin. The cell pellets were fixed with ice-cold 70% ethanol and stored at -20^0^C until further use. The fixed cells were centrifuged at 500xg for 5 min and washed twice with cold PBS to remove ethanol followed by re-suspension 0.25 ml PBS with RNase A (5 μL of 10 mg/ml) to avoid false DNA-PI staining. The cells were incubated for 1 h at 37^0^C followed by centrifugation at 500x *g* for 5 min. The pellet was re-suspended in Guava cell cycle reagent (EMD Millipore Corporation) and incubated in dark for 5 min. The stained cells were analyzed using Guava PCA flow cytometer (Millipore) and Flow Jo software (Version 7.6, Flow Jo, LLC, USA).

Apoptosis assay
---------------

MCF-7 and MDA-MB-231 cells were seeded at a density of 2 X 10^5^ cells/well in 6 well plates for 24 h followed by treatment of CAPE for 24-36 h. Apoptosis assay was examined using Guava Nexin Reagent (EMD Millipore Corporation) using procedure recommended by the manufacturer. Apoptotic cells were quantitated by Flow Jo Software.

cDNA array
----------

Total RNA was prepared using TRIzol reagent (Gibco BRL, Grand Island, NY) following manufacturer\'s instructions, and was labeled with Cy3 or Cy5 using Low Input Quick Amp Labeling Kit (Agilent Technologies), hybridized to human cDNA array slides and analyzed using Agilent 2100 BioAnalyzer series II (Hokkaido-System Science, Japan). cDNA array data on total of 22932 genes, upregulated more than 2-fold in CAPE-treated cells as compared to the control, were used to identify the most potential pathways using Gene Annotation Tool to Help Explain Relationships (Gather) [@B46] and Advaita Bio\'s iPathway Guide (<http://www.advaitabio.com/ipathwayguide>). The software analysis tool implemented the \'Impact Analysis\' approach that took into consideration the direction and type of all signals on a pathway, the position, role and type of the genes [@B47]. The genes were plotted in KEGG pathway database [@B48].

Docking studies and molecular dynamics simulation of the obtained complex
-------------------------------------------------------------------------

AutoDock 4.2 suite was utilized for molecular-docking of CAPE with mortalin. The three dimensional structure of caffeic acid phenethyl ester (CAPE) was retrieved from PubChem database (CID: 5281787). Roots were detected for CAPE, 6 bonds were made rotatable and the coordinates were saved in PDBQT file format (an extended PDB format that was utilized for storing coordinates and atomic partial charges) using AutoDock Tools. The crystal structure of mortalin \[PDB ID: 4KBO\] was obtained from PDB (<http://www.rcsb.org/pdb/home/home.do>). AutoDock Tools were utilized for preparation of crystal structure by addition of all hydrogen atoms in order to ensure correct calculation of partial atomic charges followed by calculation of Gasteiger charges. A three dimensional grid map with 60 x 60 x 60 points was generated around p53 binding site on mortalin (residues 253-282). Lamarckian Genetic Algorithm (GA) was employed with a population size of 150 dockings and energy evaluation of 2.5 x 10^6^ for performing docking step. The most stable or lowest energy conformation of the docked complex amongst all the docked structures was selected for further analysis.

To comment on the dynamic stability of CAPE within the active site of mortalin, molecular dynamics simulations were performed on the docked complex using Desmond module of Schrodinger\'s Suite and Maestro as interface [@B49],[@B50]. MD simulations were performed by applying OPLS 2005 molecular mechanics force field. At first, the protein was prepared to fix erroneous atomic representations in the complex structure. Preparation steps involved addition and optimization of hydrogen atoms, generation of disulfide bonds and capping of end terminals. The prepared protein was then solvated in a triclinic periodic box of SPC water molecules and neutralized by addition of appropriate number of counter ions. In order to eliminate geometric problems such as unrealistic bond distances, bond angles and torsion angles, energy minimization was performed. Steepest descent method with restraints was used to minimize the system until a gradient threshold of 25 kcal/mol/Å was not reached. MD simulations were performed on the equilibrated systems for a time period of 40 ns at a constant pressure and temperature with a time step of 2 fs. Root mean square deviations were calculated for the mortalin-CAPE complex during the entire simulation trajectory with reference to the first frame.

MM-GBSA analysis for the docked complex pre- and post-molecular dynamics simulations
------------------------------------------------------------------------------------

Various computational approaches are often used to calculate binding-free energies in complex bio-molecular systems. Use of scoring function of molecular docking for predicting the protein-ligand interaction and binding-free energies to identify potential lead compounds for a specific molecular target is one such approach [@B51]. Even though they are fast, some drawbacks like lack of treatment of protein flexibility and water molecules, improperly accounting for solvation, entropy, and polarizability need to be improved to achieve high scoring accuracy. MM-GBSA method that uses a single minimized protein-ligand structure instead of various frames derived from MD trajectories is an efficient method to refine and rescore docking results and calculate free binding energies [@B52]. ΔG~binding~was calculated for the mortalin-CAPE complex using MM-GBSA analysis available in Prime module of Glide [@B53].

Prediction of pharmacokinetics of CAPE in human body
----------------------------------------------------

In order to determine the drug-likeness and pharmacokinetics of CAPE, its 3D structure was analyzed to assess various physicochemical properties. Its absorption, distribution, metabolism, excretion and toxicity (ADMET) were calculated *in silico*using Qikprop module of Schrodinger suite and admetSAR, an online open access server [@B54].

Western blotting
----------------

Control and treated cells were lysed in RIPA lysis buffer (Thermo Fisher Scientific Inc., IL, USA) containing complete protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany) for 20 min on ice. Lysates were centrifuged at 15000 rpm for 15 min, and the supernatant was used for Western blotting. The protein concentrations of cell lysates were determined by BCA (Bicinchonic Acid) assay (Thermo Fisher Scientific Inc., IL, USA). The lysates (20 µg protein) were resolved on a 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, MA) using a semidry transfer blotter (ATTO Corporation, Japan). Membranes were blocked with 3% BSA/TBST and then probed with indicated antibodies: mortalin [@B45], GADD45α (H-165), p53 (DO-1), MMP-2 (H-76), vimentin (H-84) (Santa Cruz Biotechnology, CA) for overnight at 4^o^C followed by incubation with HRP conjugated-secondary antibodies (Santa Cruz Biotechnology, CA) and detection by ECL PLUS (GE Healthcare, UK). The membranes were probed by anti β-actin antibody (Abcam, UK) as an internal loading control. Protein signals were quantitated using the ImageJ software (NIH, USA). Standard deviation and statistical significance of the data were calculated by Microsoft office excel (Microsoft Corporation, WA, USA) and QuickCals t-test calculator (GraphPad Software, Inc., CA, USA), respectively. Statistical significance of the data was represented by ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001 for significant, very significant, highly significant, respectively.

Immunofluorescence
------------------

For immunofluorescence, cells (1 X 10^3^/well) were plated on glass coverslips placed in 12-well culture dish. Control and treated cells were washed twice with PBS, fixed in pre-chilled methanol:acetone (1:1) for 5 min on ice, and were then permeabilized by 0.1% Triton X-100 in PBS for 15 min. The samples were blocked with 1% bovine serum albumin in PBS, and followed by incubation in anti-mortalin [@B45] and p53 (DO-1) and GADD45α (H-165), MMP-2 (H-76), vimentin (H-84) (Santa Cruz Biotechnology, CA) p53BP-1 primary antibodies. Immunostaining was visualized by secondary staining with either Alexa-488 or Alexa-594 conjugated antibodies (Molecular probes). After three to four washings with 0.2% Triton X-100 in PBS (PBST), cells were counter stained with Hoechst for nuclear staining, overlaid with Fluoromount (Difco). Cells were examined on a Zeiss Axiovert 200 M microscope and analyzed by AxioVision 4.6 software (Carl Zeiss).

Immunoprecipitation assay
-------------------------

Cell lysates (500 μg) of control and CAPE treated cells were incubated with dyna beads**®**Protein A conjugated with anti-mortalin polyclonal antibody [@B45] for overnight at 4^o^C (Thermofisher Scientific, Life Technologies AS Oslo). The immunocomplexes (IC) were washed with PBST (PBS with 0.2% Triton X100) three times followed by elution in denaturing SDS loading buffer (25 μL) by heating at 70^o^C for 10 min. IC were resolved on 7.5% SDS-PAGE along with controls including and cell lysate (20 μg), IgG and Dyna beads, and were electro-blotted onto a PVDF membrane (Millipore Corporation) using a semi-dry transfer system (Bio-Rad). The membrane was probed with anti-p53 (DO-1; SC126) and anti-mortalin monoclonal antibodies. Proteins were detected using ECL (Enhanced Chemi Luminescence; Amersham Pharmacia Biotech). Amount of p53 in mortalin-IC was quantitated by normalizing with the amount of IgG and mortalin controls in IC.

Wound-scratch assay
-------------------

The *in vitro*migration capability of cells in response to CAPE and CAPE-γCD treatment was examined with a wound-scratch assay. The cells were grown in a monolayer and wounded by uniformly scratching the cells in a line with a 200 µl pipette tip. Cells were washed with PBS to remove cell debris or floating cells, and cultured on either the control or CAPE or CAPE-γCD-supplemented medium, respectively. The time of wound scratching was designated as time 0. Movement of cells into the wounded area was recorded during next 24 h under a phase contrast microscope with a 10 X phase objective. Migration capacity was calculated by measuring the percent of open area in 6-10 randomly captured images.

*In vitro* chemotaxis assay
---------------------------

Cells at 60-70% confluency were washed with cold PBS, trypsinized, and re-suspended in DMEM-supplemented with 0.5% bovine serum albumin (Sigma) at 5X10^4^ cells/ml. 2.5 X 10^4^ cells were plated in BioCoat^TM^Matrigel^TM^ Invasion Chambers (8-mm pore, BD Biosciences), in the presence or absence of the drugs, and the invasion assay was performed following the manufacturer\'s instructions. Cells that had invaded through the Matrigel and filters were extracted with 10% acetic acid and quantitated by absorbance at 590 nm using a microplate reader (TECAN, Switzerland).

*In vivo* anti-tumor and anti-metastasis assays
-----------------------------------------------

The tumor- and metastasis-inhibitory effect of CAPE and CAPE-γCD was assessed using nude mice subcutaneous xenografts and tail vein injection models, respectively. Balb/c nude mice (4-weeks old, female) were bought from Nihon Clea (Tokyo, Japan). Animals were acclimatized in the laboratory for one week. Cells were injected subcutaneously (1 X 10^7^ suspended in 0.2 ml of growth medium) into the abdomen of nude mice and into tail vein (1 X 10^6^ suspended in 0.2 ml of growth medium). CAPE or CAPE-γCD was administered (either intraperitoneal or oral route, as indicated) every alternate day starting one day after injection of cells. Tumor formation and body weight of mice were monitored every alternate day. Volume of the subcutaneous tumors was calculated as *V = L x W^2^*/2, where *L*was length and *W*was the width of the tumor, respectively. Statistical significance of the data was calculated from three independent experiments (n=3 per experiment). For metastasis assay, the mice were sacrificed 30 days post-injection and screened for the presence of tumors. Number of lung tumors in control and treated mice were recorded. All procedures were carried out in accordance with the Animal Experiment and Ethics Committee, Safety and Environment Management Division, National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, Japan.

Results
=======

Anticancer and anti-metastasis activity of CAPE and CAPE-gamma CD conjugate
---------------------------------------------------------------------------

We examined the cytotoxicity of CAPE to a variety of human cancer cell lines including A549, HT1080, G361, U2OS, MCF-7 and MDA-MB-231, and found that it is cytotoxic to all cancer cells in a range of 5-100 μM (Fig. [1](#F1){ref-type="fig"}A, B). Whereas most of them showed IC50 of 10-20 μM, A549 showed remarkable resistance (IC50-100 μM) and MCF-7 showed high sensitivity (IC50-5 μM) (Fig. [1](#F1){ref-type="fig"}B). In order to determine if CAPE could be used for treatment of aggressive and metastatic cancers, we used genetically isogenic breast cancer cells that differed in their cell migration and metastasis potentials.

These were generated by retrovirus-mediated overexpression of stress chaperone mortalin [@B45],[@B55]. In short- and long-term survival assays, we found that the CAPE inhibited the growth of parent as well as their metastatic-derivatives to a comparable level (Figs. [1](#F1){ref-type="fig"}B and 1C). Furthermore, we subjected control and CAPE (low and high dose) treated MCF-7 and MDA-MB-231cells to FACS analysis and found that whereas low dose (1-2 μM and 5-10 μM, respectively) of CAPE caused G1 arrest of cell cycle, high dose (5-10 μM and 25-50 μM, respectively) treatment resulted in apoptosis (Figs. [1](#F1){ref-type="fig"}D and 1E). Similar results were obtained in both parent and metastatic breast cancer cell lines suggesting that CAPE may also be used for treatment of aggressive and malignant cells.

In order to investigate the molecular mechanism of CAPE-induced cytotoxicity, we took time-lapse observations of control and CAPE-treated cells. MCF-7 cells when treated with CAPE (10 μM) showed apoptosis at about 24 h. However, dividing cells appeared at about 48-60 h and overtook the apoptotic cell population (Fig. [2](#F2){ref-type="fig"}A and data not shown) suggesting a short-term effect of CAPE that might be due to its unstable characteristic [@B56]-[@B58]. We confirmed this by regular (every 24 h) change of cell culture medium and with fresh addition of CAPE. With this treatment regime, growth arrest/apoptosis (10 μM was sustained (Fig. [2](#F2){ref-type="fig"}A and data not shown). The data confirmed that short-term effect of CAPE was due to, at least in part, its unstable characteristic. CAPE possesses reactive sites such as ester bond, α and β-unsaturated carbonyl group and catechol group that accounts for its instability in physiological conditions causing its hydrolysis, Michael addition and oxidation (Fig. [2](#F2){ref-type="fig"}B).

In order to increase the stability of CAPE, we made its complex with γCD in molar ratios of 1:1. The binding constant (*K*) for the CAPE-γCD complex was determined in 1 X 10^-1^ M phosphate buffer at pH 7.4 and 25^o^C by UV/Vis-spectroscopic-titration method. The spectral change in CAPE, endorsing formation of its complex with γCD, was first recorded (Fig. [2](#F2){ref-type="fig"}C). The analysis of the titration curve with a theoretical equation for the 1:1 conjugation provided a *K* value of (2.52 ± 0.04) x 10^3^ M^-1^ (Fig. [2](#F2){ref-type="fig"}C inset). Similar *K* values were obtained for the conjugation of CAPE and αCD or γCD (Fig. [2](#F2){ref-type="fig"}D). The thermostability of CAPE and CAPE-γCD was examined by incubating them at 140^o^C for 24 h. As expected, color change and melting were observed in the case of CAPE. On the other hand, CAPE-γCD retained its solid state and showed only a minor change in color. The enhanced thermostability of the CAPE-γCD was also confirmed by HPLC-based quantitation of CAPE in heat-treated samples (Fig. [3](#F3){ref-type="fig"}A).

To examine the stability of CAPE and CAPE-γCD against hydrolysis by α-Chymotrypsin (ChT), a protease secreted by pancreas, CAPE (50 μM) and ChT were incubated for 3 h at pH 7.4 and 25^o^C in the absence or presence of γCD (20 μM). As shown in Fig. [3](#F3){ref-type="fig"}B, decrease in CAPE and increase in caffeic acid were monitored concurrently by HPLC (Fig. [3](#F3){ref-type="fig"}B-a). The data showed that CAPE undergoes hydrolysis by α-Chymotrypsin (digestive enzyme present in gut). Of note, CAPE-γCD showed resistance to such digestion by ChT indicating its stability. Similar results were observed in assays for testing the stability of CAPE and CAPE-γCD in Michael 1,4-addition reaction with cysteine (Fig. [3](#F3){ref-type="fig"}B-b). To examine the stability of CAPE and CAPE-γCD against oxidation, potassium iodate (an established oxidant) was added to CAPE (50 μM) solution in the absence or presence of γCD (20 mM). The oxidation reaction was monitored by UV/Vis-spectroscopy (Fig. [3](#F3){ref-type="fig"}C). Generation of quinone derivative, as usually indicated by increase in the peak (around 400 nm), was not observed. Therefore, observed time-dependent spectral change in CAPE in this condition presumably indicated rapid Michael 1,4-addition reaction of quinone derivative with some nucleophile, for example H~2~O or OH^-^ following oxidation reaction as rate limiting step. Noticeably, whereas 80% of CAPE in the free form, reacted with potassium iodate in 3 h, only 40% reacted when in complex with γCD under the same condition of experiment suggesting that γCD could stabilize CAPE against oxidation (Fig. [3](#F3){ref-type="fig"}C).

Equivalent doses of CAPE in its free form and in complex with γCD were next used for cell viability studies. As shown in Fig. [4](#F4){ref-type="fig"}A, wherein γCD by itself was non-toxic to cells, CAPE showed short-term toxicity, CAPE-γCD complex showed sustained growth arrest or apoptosis suggesting that CAPE-γCD is potent than CAPE. Quantitative cell viability analysis also revealed that the equivalent dose of CAPE in its complex with γCD was more cytotoxic as compared to its free form. Similar results were obtained in the breast cancer cell lines and their metastatic derivatives (Figs. [4](#F4){ref-type="fig"}A and 4B, and data not shown). We next used sub-toxic doses of CAPE and examined their effect on cell migration (Fig. [4](#F4){ref-type="fig"}C). Wound-scratch and invasion assays on MCF-7 and MDA-MB-231 cells and their metastatic mortalin-overexpressing derivatives revealed that CAPE-γCD complex possessed stronger anti-migration activity (Figs. [4](#F4){ref-type="fig"}C and 4D). Similar result was obtained in cell invasion assays (Figs. [4](#F4){ref-type="fig"}E and 4F).

CAPE causes upregulation of DNA damage response
-----------------------------------------------

In order to determine the molecular mechanism of CAPE-induced growth arrest and anti-migration activity, we subjected the control and CAPE (10 μM)-treated MCF-7 cells to cDNA array analysis. We found that the CAPE caused upregulation and downregulation of several proteins at the transcription level. The top upregulated signaling pathways were involved in cell cycle arrest and negative regulation of cell cycle that included upregulation of GADD45α (Growth Arrest and DNA Damage-inducible, alpha), CDKN1A (Cyclin-dependent kinase inhibitor 1a (p21), DDIT3 (DNA-Damage-Inducible Transcript 3), SKIL (Ski-Like oncogene, TP53INP1 (Tumor protein p53 inducible nuclear protein 1, GATA3 (Gata binding protein 3) and RHOB (Ras homolog family member b) (Figs. [5](#F5){ref-type="fig"}A and 5B). In light of this data, we performed expression analysis of GADD45α both at protein and mRNA level. Western blotting and immunostaining revealed an upregulation of GADD45α in CAPE-treated cells (Fig. [5](#F5){ref-type="fig"}C and 5D). Furthermore, there was two-fold increase in GADD45α transcript in treated cells, suggesting that CAPE may trigger the DNA damage response in cancer cells (Fig. [5](#F5){ref-type="fig"}E). It was further confirmed by 53BP1 and γΗ2ΑX staining that revealed upregulation in CAPE, CAPE-γCD, but not in the γCD treated cells (Fig. [5](#F5){ref-type="fig"}F and data not shown).

CAPE causes upregulation of p53 function by targeting mortalin-p53 interactions
-------------------------------------------------------------------------------

Based on the fact that GADD45α is a downstream effector of p53 tumor suppressor, involved in growth arrest of cells in response to DNA damage, we hypothesized that CAPE-induced increase in GADD45α might be mediated by activation of p53. Examination of p53 in control and CAPE-treated cells indeed revealed its upregulation and nuclear translocation of p53 and increase in its downstream effector p21^WAF1^ in MCF-7, U2OS as well as A549 cells (Fig. [6](#F6){ref-type="fig"}A and data not shown). Increase in p53 and p21^WAF1^ in treated cells was confirmed by Western blotting (Fig. [6](#F6){ref-type="fig"}B). Furthermore, p53-dependent reporter assays revealed increase in transcriptional activation function of p53 in CAPE-treated cells (Fig. [6](#F6){ref-type="fig"}C). We next predicted that the increase in p53 might be due to targeting of mortalin, a stress chaperone known to inhibit p53 activities [@B45],[@B55],[@B59]-[@B62] by CAPE. Using bioinformatics and molecular docking tools, we examined whether CAPE could bind to mortalin and interfere with mortalin-p53 interaction as follows.

The 3D structure of CAPE was docked at the desired grid coordinates of the protein molecule using Lamarckian Genetic Algorithm (GA) of AutoDock Tools. The compound showed good binding affinity with the p53-binding domain of mortalin possessing a docking score of -5.72 kcal/mol, i.e. binding energy of -23.93 kJ/mol approximately. The residues from 258 to 282 of mortalin are involved in interaction with p53. CAPE was found interacting with many of these important residues via hydrogen bonds and hydrophobic interactions (Fig. [7](#F7){ref-type="fig"}A). Nitrogen (NZ) of residue Lys 135 formed two hydrogen bonds of 2.59 Å and 3.32 Å with third and fourth oxygen atom of CAPE respectively while oxygen atom (OG1) of Thr 271 formed one H-bond of 2.61 Å with third oxygen of CAPE. The residues participating in maintaining a hydrophobic contact with CAPE involved Tyr 196, Phe 250, Asp 251, Thr 267, Asn 268, Gly 269, Asp 270 and Phe 272. Since the ligand molecule CAPE was occupying the mortalin cavity where p53 binds, it was strongly suggestive that mortalin-CAPE interaction would hinder the mortalin-p53 interface and thereby inhibit sequestration of p53 in the cytoplasm resulting into its nuclear translocation and activation. The maestro pose viewer file obtained after docking of CAPE with mortalin was used as an input for MM-GBSA analysis. Using the MM-GBSA method on the docked complex, free energy of binding (ΔG~binding~) was calculated using the following formula: ΔG~binding~= Energy of the minimized complex - (Energy of the minimized ligand + Energy of the minimized receptor). The free energy of binding for the docked complex by MM-GBSA method was estimated to be -9.74 kcal/mol suggesting that binding of CAPE with mortalin is a thermodynamically favorable process.

Changes in interaction pattern were revealed by thermodynamic stability analysis of mortalin-CAPE complex in a 40 ns long MD simulation run. The protein backbone in the complex deviated about 2.0 Å from its initial state during the first 5 ns of the simulation run and then attained a stable conformation for the rest 35 ns (Fig. [7](#F7){ref-type="fig"}B). Figure [7](#F7){ref-type="fig"}C illustrates the change in position of CAPE during the course of a 40 ns simulation run. Even though the location of ligand was same, it attained different conformations to reach its final energetically stable state. The frame representing the average of all the frames for the last 30 ns was obtained and used for further analysis. It was observed that the ligand moved deeper into one of the buried cavity of the protein structure. CAPE was stably interacting with the protein with the help of hydrophobic and van der Waal interactions. The amino acid residues of mortalin involved in this binding included Tyr 196, Phe 250, Asp 251, Thr 267, Asn 268, Gly 269, Asp 270, Thr 271 (Fig. [7](#F7){ref-type="fig"}C). Many of these residues were interacting even before the MD simulations and are a part of crucial p53 binding domain of mortalin. The free energy of binding was calculated and estimated to be -17.87 kcal/mol for post MD complex endorsing that binding of CAPE with mortalin protein is a thermodynamically favorable process. Based on this data, it was strongly predicted that CAPE targets mortalin-p53 complex and causes reactivation of p53 function as shown in Fig. [6](#F6){ref-type="fig"}. Furthermore, we performed validation of this prediction by co-immunostaining and co-immunoprecipitation of mortalin and p53 in control and CAPE-treated cells. As compared to the control, CAPE treated cells showed intense nuclear staining (Fig. [7](#F7){ref-type="fig"}D) and possessed decreased amount of p53 in mortalin-p53 complexes (Fig. [7](#F7){ref-type="fig"}E and data not shown).

CAPE causes downregulation of metastasis signaling
--------------------------------------------------

Mortalin is enriched in cancer cells, and has been shown to promote carcinogenesis and metastasis signaling [@B45],[@B55],[@B59]-[@B62]. We next examined the expression level of mortalin in control and CAPE-treated cells. As shown in Fig. [8](#F8){ref-type="fig"}A-C, there was a decrease in mortalin at both protein and transcript level in CAPE-treated cells. We examined the expression level of key regulators of cell migration in these cells and found decrease in vimentin, MMP-2, MMP-3, β-catenin, TGF-β and WNT-3α transcripts (Figs. [8](#F8){ref-type="fig"}C and 8D). Of note, CAPE-γCD treated cells showed higher decrease (Figs. [8](#F8){ref-type="fig"}A and 8B).

*In vivo* tumor suppressor and anti-metastasis activities of CAPE and CAPE-γCD complex
--------------------------------------------------------------------------------------

We finally investigated anticancer and anti-metastasis potential of CAPE and CAPE-γCD complex in *in vivo* tumor assays in nude mice. An established model cell line (human fibrosarcoma, HT1080) was used for subcutaneous xenografts (for tumor growth) and tail vein injections (lung metastasis) (Fig. [9](#F9){ref-type="fig"}). CAPE showed significant tumor suppression in subcutaneous xenografts. Whereas γCD itself did not show any effect, CAPE-γCD showed stronger activity than CAPE when administration either by intraperitonial injections or gavage. Examination of lung metastasis in control, CAPE and CAPE-γCD treated mice revealed stronger anti-metastasis activity by CAPE-γCD complex. In both routes of administration, whereas CAPE-treated mice showed significant reduction in lung metastasis there was significantly enhanced effect in response to treatment with CAPE-γCD.

Physicochemical properties and pharmacokinetics of CAPE
-------------------------------------------------------

QikProp predicts physically significant descriptors and pharmaceutically relevant properties of organic molecules. It also provides significant ranges for comparing these molecular properties with those of 95% of already known pharmaceutical drugs. It gives a descriptor "\#star" which denotes the number of properties of the organic molecule which do not fall within the range of values for same properties of already known drugs. According to this predictive algorithm, lower the number better is the drug-likeness of the small molecule. The \#star value for CAPE was 0. Hence, none of the computed property lied outside the required range and was very similar to that of the known drugs. Lipinski\'s rule of five is a thumb rule that determines the likeliness of being a drug using four molecular properties. CAPE with a molecular mass of 284.31 g/mol, 2 hydrogen bond donors, 3.5 hydrogen bond acceptors and an octanol/water partition coefficient of 3.18 full-filled all the conditions of rule of five.

Solvent accessible surface area (SASA) and especially polar surface area (PSA) is known to have a good correlation with the passive molecular transport through membranes and therefore allows estimation of transport properties for drugs. The total SASA for CAPE was 607.45 Å^2^ with hydrophobic component of 97.271 Å^2^and hydrophilic component of 162.901 Å^2^. These values were well within the range given by QuickProp. It also calculates the percentage probability of the drug getting orally absorbed in the human body using some knowledge based set of rules. This value has been shown to correlate well with the human oral absorption. CAPE showed high oral absorption with a percentage value of 89.30%. It was also predicted to be inactive against the central nervous system. Some other toxicity related effects were predicted using an online free platform, AdmetSAR. Blood brain barrier (BBB) is a regulatory system that separates the brain environment from the direct contact of circulatory system thereby protecting the brain for unwanted solute particles. CAPE was shown to be BBB negative ensuring its administration safe for the brain. Induction of the P-glycoprotein (P-gp), an efflux transporter, leads to reduced bioavailability of orally administered drugs and can therefore decrease is therapeutic efficacy. Alternatively, its inhibition can also result in increased bioavailability, thus leading to an increased risk of adverse side effects. Thus, in general a drug should be neither a substrate nor an inhibitor of P-gp. It is expected that P-gp would not act as a barrier for the systemic exposure of CAPE as it was predicted to be a non-substrate and non-inhibitor of P-gp. It was also shown to be non-carcinogenic and readily biodegradable with some levels of toxicity in *Tetrahymena pyriformis*, fish and honeybee.

Discussion
==========

Anti-tumor and anti-metastatic potency of CAPE was increased by γCD
-------------------------------------------------------------------

The *in vitro*cytotoxicity assays of CAPE on a variety of cancer cell lines revealed that it possesses anticancer activity; the range of cytotoxic doses for different cancer cells lines was consistent with other reports [@B15],[@B18],[@B26],[@B29],[@B41],[@B58]. Taken together, it was suggestive that the toxicity of CAPE is widespread rather than being specific to certain cancer cell lines. Furthermore, by using metastatic cells, we found that CAPE is effective not only for inhibiting the growth of cancer cells but also for metastasis (Figs. [4](#F4){ref-type="fig"}, [8](#F8){ref-type="fig"} and 9). Computational and molecular analyses revealed that CAPE targets mortalin-p53 interactions that are specific to cancer cells [@B45],[@B46] and hence may account for, at least in part, for selective toxicity of CAPE to cancer cells in several earlier studies [@B17]-[@B20]. It has been earlier shown that mortalin interacts and inactivates wild as well as mutant p53 proteins. Abrogation of these interactions resulted in activation of growth arrest and apoptotic activities of wild and mutant p53 proteins, respectively [@B60],[@B61]. Taken together, it is suggestive that CAPE could be used for treatment of both wild type as well as mutant p53 harboring cancer cells. Furthermore, CAPE-treated cells showed down-regulation of mortalin, that is enriched in cancer cells and has been shown to contribute to carcinogenesis and metastasis, suggesting that it is an anti-mortalin molecule suitable for cancer and metastatic cell therapy [@B55],[@B59]-[@B62].

Based on the reports that the bioavailability of several lipophilic ingredients, such as coenzyme Q10, tocotrienol and curcumin, could be enhanced by their conjugation/complex with γCD, Terao and co-workers reported that such enhancement of bioavailability was due to increase in water solubility of the lipophilic ingredients by γCD in micelle solution [@B63]. Sodium taurocholate (Na TCA), a major component of bile acid, in small intestine was also shown to increase of water solubility of CAPE-γCD by similar mechanism [@B63]. Taken together, these data revealed that the instability of CAPE could be compensated by generation of its complex with γCD leading to its increased solubilization, protection and enhanced bioavailability. We next investigated the hypothesis by *in vitro* and *in vivo* experiments.

The mechanisms of the anti-tumor activity in CAPE have not been clarified. It was shown to suppress 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and induce apoptosis in mouse epidermal cells through p53-dependent and p53-independent pathways [@B64]. It was shown to inhibit production of nitric oxide and iNOS protein expression (involved in inflammatory and autoimmune-mediated tissue destruction) induced by lipopolysaccharide (LPS) plus interferon-gamma (IFN-gamma), and cause anti-inflammatory, anti-viral and anticancer effects [@B65], CAPE treatment-induced cell cycle arrest and growth inhibition were shown to be mediated via activation of Skp2, p53, p21Cip1 and p27Kip1 proteins [@B66]. It was shown to inhibit NFkB, activate MAPK family proteins p38 and JNK resulting in apoptosis [@B67]. Anti-metastasis activity of CAPE (decreased expression of matrix metalloproteinases) was supported by earlier studies [@B68]-[@B71]. Taken together and in addition to these reports, we demonstrate that CAPE targets stress chaperone mortalin leading to (i) activation of growth arrest through p53-GADD45α-p21 signaling and (ii) suppression of cell migration through matrix metalloproteinases. Furthermore, such activities could significantly be enhanced by CAPE-γCD complex that protected it from degradation. In *in vivo* antitumor assays, CAPE-γCD complex (used either by intraperitoneal injections or by oral feeding) resulted in better anti-tumor outcomes in *in vivo* assays and hence it is proposed as a potent anticancer reagent.
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![**Cytotoxicity of CAPE to human cancer cells.**Dose dependent loss in cell viability in cells treated with CAPE is shown. IC50 for A549, HT1080, G361 and U20S were \~100, 5, 20, 60 μM respectively (A). Effect of CAPE on cell viability (B) and colony forming efficiency (C) of MCF-7, MDA-MB-231 cells and their mortalin-overexpressing metastatic deriatives showing that CAPE inhibited cell proliferation in both short (A) and long term (B) viability assays. (D) Cell cycle analysis of control and CAPE-treated cells showing G1 arrest both in MCF-7 and MDA-MB-231 treated with low dose (2 μM and 10 μM CAPE, respectively) of CAPE. (E) High dose (10 μM and 40 μM CAPE, respectively) caused apoptosis.](jcav07p1755g001){#F1}

![**Instability of CAPE in cell culture medium and its complex with γCD.** (A) Phase contrast images of MCF-7 cells treated with CAPE either one time or regularly (every 24 h) for total of 72 h. Whereas healthy dividing cells appeared in culures treated for only once, the regularly treated cultures showed growth arrest/apoptosis. (B) Reactive sites of CAPE, such as ester bond, α, β-unsaturated carbonyl and catechol group, that accounts for its unstability are shown. (C) The binding constant (*K*) for the complexation of CAPE with βCD, as by a UV/Vis-spectroscopic-titration method is shown. The analysis of the titration curve revealed 1:1 complexation provided a *K* value of (2.52 ± 0.04) x 10^3^ M^-1^ (inset). (D) Binding constant (*K)* values of complex of CAPE with αCD or γCD.](jcav07p1755g002){#F2}

![**Characterization of CAPE-γCD complex and its stability to various adverse conditions.**(A) Thermostability analyis at 140^o^C at 24 h showing color change and melting of CAPE, but not CAPE-γCD. The enhanced thermostability was also observed from the analysis of contents of CAPE in heat-treated samples by HPLC. (B) Stability of CAPE and CAPE-γCD against hydrolysis by α-Chymotrypsin (ChT) for 3 h at pH 7.4 and 25^o^C. Decrease in CAPE and increase in caffeic acid were concurrently observed (a). CAPE-γCD indicated much higher stability than CAPE. Stabilization of CAPE against Michael 1,4-addition reaction with cysteine by γCD (is shown (b). (C) Stability of CAPE and CAPE-γCD against oxidation as monitored by addition of potassium iodate and UV/Vis-spectroscopy. Large proportion of CAPE (80%) reacted with potassium iodate in incubation. In case of CAPE-γCD, 40% CAPE reacted and 60% was protected in the same condition.](jcav07p1755g003){#F3}

![**Anticancer potential of CAPE and CAPE-γCD complex.** (A) Effect of CAPE, γCD and CAPE-γCD on viability, migration and invasion of MCF7 and MDA-MB-231 cells. Phase contrast images (A), cell viability (B) migration in wound scratch (C&D) and cell invasion assay (E&F) are shown.](jcav07p1755g004){#F4}

![**Characterization of CAPE cytotoxicity by cDNA array analysis.** (A) Pathways derived from cDNA array analysis; genes upregulated (Red) and downregulated (green) in CAPE treated as compared to the control cells. (B) Genes upreguleated in CAPE treated cells as determined by cDNA array analysis. (C) Immunostaining of GADD45α in control and CAPE treated cells showing increase in the latter. Increase in GADD45α in CAPE and CAPE-γCD treated cells detected by Western blotting (D) and RT-PCR. (E) 53BP1 immunostaining showing increase in CAPE-γCD tretaed cells.](jcav07p1755g005){#F5}

![**Activation of p53-p21 pathway by CAPE.** (A) Immunostaining of p53 and p21 in control and CAPE treated cells showing their increase. (B) Increase in p53 and p21 as determined by Western blotting with specific antibodies. (C) p53-dependent reporter assay showing increase in transcriptional activation function of p53 in CAPE-treated than in control cells.](jcav07p1755g006){#F6}

![**Molecular docking analysis of CAPE and mortalin.** (A) Amino acid residues of mortalin participating in hydrogen bond (pink), hydrophobic and van der Waal interactions (orange) wih CAPE after molecular docking. (B) Graph showing deviation of the docked complex from its initial conformation during the complete simulation run. (C) Molecular interaction pattern between mortalin and CAPE after simulation. Residues were mainly involved in hydrophobic and van der Waal interactions (shown in orange). Change in position of CAPE can be observed. The ligand showed variations in the orientation and hence an average representative structure from the stable time frame was used for interaction analysis. (D) p53 immunostaining of MCF7 control and CAPE treated cells showing intense nuclear staining in the later. (E) Relative amount of p53 in mortalin-p53 complex in control and CAPE-treated cells showing decrease in mortalin-p53 complex in the latter.](jcav07p1755g007){#F7}

![**Downregulation of mortalin and other metastasis-regulatory proteins by CAPE.** Effect of CAPE on mortalin and cell migration regulatory proteins. Decrease in mortalin, vimentin, MMP-2 was obserevd by Western blotting (A), immunostaining (B) and RT-PCR (C). Decrease in mortalin, vimentin, β-catenin, TGF-β and Wnt-3α as determined by qPCR is shown (D).](jcav07p1755g008){#F8}

![***In vivo* anti-tumor and anti-metastasis activties of CAPE and CAPE-γCD complex.**Effect of CAPE and CAPE-γCD on *in vivo* progression of tumors generating either by subcutaneous xenografts or tail vein injections of HT1080 in nude mice. Tumor volumes showed decrease in mice treated with CAPE and CAPE-γCD complex (either peritoneal injections or gavage). CAPE-γCD treated mice showed higher degree of tumor suppression in both models. No effect on the body weight was observed.](jcav07p1755g009){#F9}
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